Similarly, elevated GLUT1 expression is strongly correlated with tumour hypoxia, glycolytic metabolism, and resistance to conventional therapies, making it an attractive candidate for patient selection and monitoring [91]. This evidence concerns the gene SLC2A1 and neoplasm.